Compare · AGTI vs CLBS
AGTI vs CLBS
Side-by-side comparison of Agiliti Inc. (AGTI) and Caladrius Biosciences Inc. (CLBS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGTI and CLBS operate in Managed Health Care (Health Care), so they compete in similar markets.
- AGTI is the larger of the two at $2.40B, about 55.0x CLBS ($43.6M).
- AGTI has more recent analyst coverage (20 ratings vs 0 for CLBS).
- Company
- Agiliti Inc.
- Caladrius Biosciences Inc.
- Price
- $10.07-0.20%
- $6.45+1176.72%
- Market cap
- $2.40B
- $43.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Managed Health Care
- Managed Health Care
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 20
- 0
Agiliti Inc.
Agiliti, Inc. provides healthcare technology management and service solutions to the healthcare industry in the United States. The company offers onsite managed services, including programs for the management, reprocessing, and logistics of medical equipment at individual facilities and integrated delivery networks to monitor and adjust equipment quantities and availability to address fluctuations in patient census and acuity; and clinical engineering services comprising maintenance, repair, and remediation solutions for various type of medical equipment, including general biomedical and diagnostic imaging equipment through supplemental and outsourced offerings. It also provides equipment solutions, which primarily provide supplemental, peak need, and per-case rental of general biomedical, specialty, and surgical equipment to acute care hospitals and alternate site providers, including premier healthcare institutions and integrated delivery networks. As of December 31, 2020, it owned or managed approximately a million units of medical equipment for approximately 7,000 national, regional, and local acute care hospitals, health system integrated delivery networks, and alternate site providers. Agiliti, Inc. was founded in 2018 and is headquartered in Minneapolis, Minnesota.
Caladrius Biosciences Inc.
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Latest AGTI
- SEC Form 15-12G filed by Agiliti Inc.
- SEC Form EFFECT filed by Agiliti Inc.
- DigitalOcean Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
- SEC Form 10-Q filed by Agiliti Inc.
- SEC Form 25-NSE filed by Agiliti Inc.
- Harris C Martin returned $191,500 worth of shares to the company (19,150 units at $10.00), closing all direct ownership in the company (SEC Form 4)
- Patrick Diane B. returned $369,010 worth of shares to the company (36,901 units at $10.00), closing all direct ownership in the company (SEC Form 4)
- Friedman Darren M. returned $118,000 worth of shares to the company (11,800 units at $10.00), closing all direct ownership in the company (SEC Form 4)
- Gottlieb Gary L. returned $513,440 worth of shares to the company (51,344 units at $10.00), closing all direct ownership in the company (SEC Form 4)
- Thl Agiliti Llc returned 98,195,398 shares to the company (SEC Form 4)
Latest CLBS
- SEC Form 4: Mazzo David J covered exercise/tax liability with 397 shares, decreasing direct ownership by 0.41% to 96,543 units
- SEC Form 4: Mazzo David J covered exercise/tax liability with 1,030 shares, decreasing direct ownership by 1% to 96,940 units
- SEC Form 4: Ruoslahti Erkki was granted 20,000 shares
- SEC Form 4: Klosk Steven M was granted 20,000 shares, increasing direct ownership by 198% to 30,090 units
- SEC Form 4: Henson Heidi was granted 20,000 shares
- SEC Form 4: Flowers Cynthia Louise was granted 20,000 shares, increasing direct ownership by 206% to 29,721 units
- SEC Form 4: Brown Gregory B was granted 20,000 shares, increasing direct ownership by 201% to 29,934 units
- SEC Form 4: Azab Mohammad was granted 20,000 shares, increasing direct ownership by 104% to 39,200 units
- SEC Form 4: Slack David W. was granted 24,000 shares and covered exercise/tax liability with 3,358 shares
- SEC Form 4: Mazzo David J was granted 60,000 shares and covered exercise/tax liability with 11,315 shares, increasing direct ownership by 99% to 97,970 units